|
nasdaq:bvxv
|
725313
|
Apr 21st, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 20th, 2024 11:05PM
|
Apr 20th, 2024 11:05PM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 20th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 19th, 2024 11:05PM
|
Apr 20th, 2024 04:41PM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 19th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 18th, 2024 11:13PM
|
Apr 18th, 2024 11:13PM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 18th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 17th, 2024 11:10PM
|
Apr 18th, 2024 06:01PM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 17th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 16th, 2024 11:00PM
|
Apr 17th, 2024 02:25PM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 16th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 15th, 2024 10:54PM
|
Apr 16th, 2024 10:41AM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 15th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 14th, 2024 10:54PM
|
Apr 15th, 2024 04:23PM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 14th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 13th, 2024 10:43PM
|
Apr 13th, 2024 10:43PM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 13th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 12th, 2024 10:34PM
|
Apr 13th, 2024 11:09AM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|
|
nasdaq:bvxv
|
725313
|
Apr 12th, 2024 12:00AM
|
Scinai Immunotherapeutics Ltd.
|
3.0K
|
36.00
|
Open
|
|
Apr 11th, 2024 10:38PM
|
Apr 12th, 2024 08:05AM
|
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
|
Open
|
BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, and Immunotherapeutics
|
Open
|
Jerusalem BioPark
|
Jerusalem
|
Jerusalem
|
IL
|
00000
|
|
BiondVax Pharmaceuticals
|
|
|